Home » Topics » BioWorld Science

BioWorld Science
RSS

Soligenix initiates phase Ic study of RiVax

Dec. 13, 2019

Prescient presents promising interim phase Ib data for PTX-200 in ovarian cancer

Dec. 13, 2019

Positive interim safety data presented from ongoing phase Ib/IIa study of ATYR-1923

Dec. 13, 2019

Phase Ib data for carfilzomib plus chemotherapy in children with refractory ALL

Dec. 13, 2019

EGFL7 as a new therapeutic target in AML

Dec. 13, 2019

TDP-43-mediated splicing repression as a therapeutic target for ALS-FTD

Dec. 13, 2019

Phase I data presented for the novel M1 mAChR modulator VU-319

Dec. 13, 2019

Manageable safety and activity seen with GDC-0077 combination treatments in phase Ib study

Dec. 13, 2019

Improbability research yields path to HIV vaccine

Dec. 13, 2019

Emergex advances early development of vaccine candidate against F. tularensis

Dec. 12, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 7, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...